For example, plasma levels of phosphorylated tau (p-tau) in AD have gained attention as a promising biomarker that correlates strongly with tau pathology and cognitive decline, offering an advantage over traditional CSF biomarkers (34). Here, MAPT is linked to Alzheimer disease.